Preclinical evaluation of PHH-1V vaccine candidate against SARS-CoV-2 in non-human primates

Prenafeta, Antoni; Cebollada Rica, Paula; Sisteré-Oró, Marta; Meyerhans, Andreas; Ferrer, Laura

doi:http://dx.doi.org/10.1016/j.isci.2023.107224

Preclinical evaluation of PHH-1V vaccine candidate against SARS-CoV-2 in non-human primates

License

Citation

Prenafeta A, Bech-Sàbat G, Moros A, Barreiro A, Fernández A, Cañete M, et al. Preclinical evaluation of PHH-1V vaccine candidate against SARS-CoV-2 in non-human primates. iScience. 2023 Jun 28;26(7):107224. DOI: 10.1016/j.isci.2023.107224

Abstract

SARS-CoV-2 emerged in December 2019 and quickly spread worldwide, continuously striking with an unpredictable evolution. Despite the success in vaccine production and mass vaccination programs, the situation is not still completely controlled, and therefore accessible second-generation vaccines are required to mitigate the pandemic. We previously developed an adjuvanted vaccine candidate coded PHH-1V, based on a heterodimer fusion protein comprising the RBD domain of two SARS-CoV-2 variants. Here, we report data on the efficacy, safety, and immunogenicity of PHH-1V in cynomolgus macaques. PHH-1V prime-boost vaccination induces high levels of RBD-specific IgG binding and neutralizing antibodies against several SARS-CoV-2 variants, as well as a balanced Th1/Th2 cellular immune response. Remarkably, PHH-1V vaccination prevents SARS-CoV-2 replication in the lower respiratory tract and significantly reduces viral load in the upper respiratory tract after an experimental infection. These results highlight the potential use of the PHH-1V vaccine in humans, currently undergoing Phase III clinical trials.